May is #BrainTumorAwarenessMonth ! The goal is to share information about brain and spine tumors to raise awareness, educate the community, and help people living with these cancers. Learn more here: bit.ly/3xFdU4f

$CNSP #BTAM #GlioblastomaMultiforme #GBM #Oncology

We will be attending the LSX World Congress happening April 29-30 in London! We look forward to a productive time with industry peers.

$CNSP #GlioblastomaMultiforme #GBM #Oncology

Grab your lunch and get ready for our Virtual Investor Lunch Break: The CNSP Opportunity happening today at 12 PM ET! Register here: bit.ly/44efENZ

@CNS_Pharma $CNSP #GlioblastomaMultiforme #GBM #Oncology

Grab your lunch and join us today at 12 PM ET for the Virtual Investor Lunch Break: The CNSP Opportunity! Register here: bit.ly/44efENZ

$CNSP #GlioblastomaMultiforme #GBM #Oncology

CNS Pharmaceuticals to Present at the LSX World Congress 2024

bit.ly/3vVlabL
$CNSP #GBM #GlioblastomeMultiforme #Oncology

#MarkYourCalendars for our Virtual Investor Lunch Break: The CNSP Opportunity on 4/23 at 12 PM ET. Register here: bit.ly/44efENZ

$CNSP @CNS_Pharma #GlioblastomaMultiforme #GBM #Oncology

CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity

bit.ly/4d9SjRs
$CNSP #GBM #GlioblastomaMultiforme #Oncology

Want to follow our progress? Sign up for email alerts here: bit.ly/446hO2j

$CNSP #GlioblastomaMultiforme #GBM #Oncology

View our webcast presentation at the LD Micro Invitational XIV today at 1 PM ET. Access it here: bit.ly/3vDON0X

$CNSP #GlioblastomaMultiforme #GBM #Oncology

We are pleased to be presenting at the LD Micro Invitational XIV on Tuesday, April 9 at 1 PM ET. Hope to see you all there!

bit.ly/3vDON0X

$CNSP #GlioblastomaMultiforme #GBM #Oncology

We are looking forward to presenting at the MedInvest Biotech & Pharma Investor Conference happening April 3-4 in New York City! Hope to see you there.

$CNSP #GlioblastomaMultiforme #GBM #Oncology

April is #CancerControlMonth . The common goal of this month is to bring awareness the importance of improving cancer treatments and increasing the survival rate of cancer. Learn more here: bit.ly/3wYRIkZ ​

$CNSP #GlioblastomaMultiforme #GBM #Oncology

CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements

bit.ly/43JnajD
$CNSP #GBM #GlioblastomaMultiforme #Oncology

CNS Pharmaceuticals to Present at Two Investor Conferences in April

bit.ly/43EETZE
$CNSP #GBM #Glioblastoma #Glioblastoma Multiforme

Learn more about #Glioblastoma and what we are doing to potentially address it here: bit.ly/49e90cb

$CNSP #Glioblastoma Multiforme #GBM #Oncology

#GBMStat Despite first being identified in the scientific literature in the 1920’s, there have only been four drugs and one device ever approved by the FDA specifically for the treatment of #glioblastoma .

$CNSP #GlioblastomaMultiforme #Oncology

#DidYouKnow The five-year survival rate for #glioblastoma patients is only 6.9%, and the average length of survival for glioblastoma patients is estimated to be only 8 months.

bit.ly/3ZWWubF
$CNSP #GlioblastomaMultiforme #GBM #Oncology

#DidYouKnow : #GBM accounts for 50.1 percent of all primary malignant brain tumors.

$CNSP #GlioblastomaMultiforme #GBM #Oncology

Our lead product candidate is currently in development for the treatment of #glioblastomamultiforme ( #GBM ), an aggressive and incurable form of brain cancer.

bit.ly/3npZn3X $CNSP

CNS Pharmaceuticals a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system malignancies.

$CNSP #GlioblastomaMultiforme #GBM #Oncology